An Investigational Scan ([89Zr]Zr-DFO-Emapalumab PET/CT) for Tumor Detection and Prediction of Treatment Response in Patients with Non-small Cell Lung Cancer

Inclusion Criteria

• Prior histologic or cytologic diagnosis of non-small cell lung cancer.
• Patients with fludeoxyglucose F-18 (FDG) PET done within 2 months of the baseline imaging, as part of standard-of-care.
• Patients with NSCLC who have not received prior immunotherapy for the current stage of diagnosis. Those who have received immunotherapy in neoadjuvant or adjuvant setting and have disease recurrence at least 12 months following completion of immunotherapy are eligible to participate following discussion with the principal investigator (PI).
• Patients with measurable disease by RECIST 1.1 with at least one lesion of at least 2 cm in a region of the body that can be imaged by PET (e.g., outside of the liver).
• Patients must be able to lie still for the tests. Their girth and weight must be suitable to enter the gantry, which varies per tomography.
• Patients must be ≥ 18 years old.
• Women of childbearing potential must not be pregnant or breastfeeding. * A negative serum pregnancy test must be obtained in women with childbearing potential within 7 days prior to the first PET scan. Men and women with reproductive potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) on study entry and for the duration of study participation.
• Patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the cancer center.
• Physical exam, complete blood count (CBC) and multiphasic (including electrolytes, blood urea nitrogen (BUN), creatinine, total bilirubin, aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) must be done within 28 days prior to PET imaging, but eligibility is not restricted by these results. The CBC and multiphasic may be drawn at the time of imaging.